NBSE
Price:
$0.378
Market Cap:
$1.42M
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pi...[Read more]
Industry
Biotechnology
IPO Date
2004-05-28
Stock Exchange
NASDAQ
Ticker
NBSE
According to NeuBase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -5817093.00. This represents a change of 27.05% compared to the average of -4578657.85 of the last 4 quarters.
The mean historical Enterprise Value of NeuBase Therapeutics, Inc. over the last ten years is 64.27M. The current -5817093.00 Enterprise Value has changed -1005.10% with respect to the historical average. Over the past ten years (40 quarters), NBSE's Enterprise Value was at its highest in in the March 2014 quarter at 272.15M. The Enterprise Value was at its lowest in in the June 2023 quarter at -6108147.71.
Average
64.27M
Median
50.99M
Minimum
-4324341.20
Maximum
147.35M
Discovering the peaks and valleys of NeuBase Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 334.56%
Maximum Annual Enterprise Value = 147.35M
Minimum Annual Increase = -108.28%
Minimum Annual Enterprise Value = -4324341.20
Year | Enterprise Value | Change |
---|---|---|
2022 | -4324341.20 | -108.28% |
2021 | 52.22M | -55.39% |
2020 | 117.06M | 276.60% |
2019 | 31.08M | 334.56% |
2018 | 7.15M | -63.39% |
2017 | 19.54M | -74.38% |
2016 | 76.26M | 53.29% |
2015 | 49.75M | -66.24% |
2014 | 147.35M | 0.50% |
2013 | 146.61M | 240.10% |
The current Enterprise Value of NeuBase Therapeutics, Inc. (NBSE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
54.99M
5-year avg
40.64M
10-year avg
64.27M
NeuBase Therapeutics, Inc.’s Enterprise Value is less than Immix Biopharma, Inc. (20.49M), less than CNS Pharmaceuticals, Inc. (2.61M), less than eFFECTOR Therapeutics, Inc. (3.64M), less than Navidea Biopharmaceuticals, Inc. (-2555017.00), less than Sonnet BioTherapeutics Holdings, Inc. (-448232.00), less than Kiromic BioPharma, Inc. (0), less than ZyVersa Therapeutics, Inc. (10.92M), less than YS Biopharma Co., Ltd. (1.84M), less than BiomX Inc. (1.70B), greater than Landos Biopharma, Inc. (-9780892.00), less than Apexigen, Inc. (42.62M), less than Angion Biomedica Corp. (205.32K), less than Monte Rosa Therapeutics, Inc. (22.43M), less than NewAmsterdam Pharma Company N.V. (478.04M), less than Inventiva S.A. (1.09B), less than Cullinan Oncology, Inc. (230.98M), less than Compass Therapeutics, Inc. (810.70M), less than null (211.64M),
Company | Enterprise Value | Market cap |
---|---|---|
20.49M | $43.37M | |
2.61M | $3.98M | |
3.64M | $1.88K | |
-2555017.00 | $50.04K | |
-448232.00 | $2.96M | |
0 | $1.73M | |
10.92M | $1.96M | |
1.84M | $192.09M | |
1.70B | $13.04M | |
-9780892.00 | $71.68M | |
42.62M | $9.57M | |
205.32K | $30.11M | |
22.43M | $542.54M | |
478.04M | $1.62B | |
1.09B | $239.85M | |
230.98M | $922.99M | |
810.70M | $233.90M | |
211.64M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuBase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuBase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NeuBase Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for NeuBase Therapeutics, Inc. (NBSE)?
What is the 3-year average Enterprise Value for NeuBase Therapeutics, Inc. (NBSE)?
What is the 5-year average Enterprise Value for NeuBase Therapeutics, Inc. (NBSE)?
How does the current Enterprise Value for NeuBase Therapeutics, Inc. (NBSE) compare to its historical average?